January 23, 2019

Ferring Pharmaceuticals appoints Sophie Opdyke to lead its new U.S. oncology division

  • Sophie Opdyke will be responsible for building Ferring’s new U.S. oncology division, leading its day-to-day operations, and shaping its long-term strategic business plan
  • Opdyke’s role is Ferring’s first major executive appointment of 2019 in the U.S.

Parsippany, N.J., USA, January 23, 2019 – Ferring Pharmaceuticals (U.S.) announced today that it has appointed Sophie Opdyke, Pharm.D., MBA as Vice President, General Manager, Oncology, effective immediately. She most recently served as Vice President, Immuno-Oncology Lead at Pfizer.

Opdyke’s role is Ferring’s first major executive appointment of 2019. She will be responsible for building the U.S. division, leading its day-to-day operations, and shaping its long-term strategic business plan. This includes leading the potential commercial launch of an investigational gene therapy for bladder cancer patients.

Opdyke has more than 20 years of experience in the pharmaceutical industry. Most recently at Pfizer, she led the development and execution of Pfizer’s strategy in Immuno-Oncology. Specifically, she oversaw all associated commercial activities from pre-clinical through launch for the company’s portfolio, including check point inhibitors, novel Immuno-Oncology targets and innovative technologies such as allogenic CAR-T and immune therapy-based vaccines. During her tenure, Opdyke was also instrumental in building and leading Pfizer’s Global Biosimilars organization, driving a core component of its biotherapeutics strategy.

“We’re delighted to welcome Sophie as the leader of our new oncology division as we prepare for a significant expansion of our presence in this area,” said Paul Navarre, CEO, Ferring Pharmaceuticals (U.S.). “Sophie’s depth of oncology experience and expertise are a significant asset to our U.S. leadership team.”

Opdyke holds a doctorate of Pharmacy and Master of Pharmaceutical Business from Université Paris Descartes and an MBA in finance and international business from Columbia Business School. She will report to Paul Navarre, CEO, Ferring Pharmaceuticals (U.S.).

###

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, women’s health, urology, gastroenterology, endocrinology, oncology, and orthopaedics. For more information, call 1-888-FERRING (1-888-337-7464); visit www.FerringUSA.com

For more information, please contact

 Patrick Gorman                                                             
Director, Corporate Communications
(862) 286-5035 (direct)

(973) 722-6335 (mobile)
patrick.gorman@ferring.com

GC/048/2019/US January 201

This site contains material about Ferring Pharmaceuticals Inc. (hereinafter "Ferring") and its various products that may be of interest to Ferring's employees and customers, as well as to members of the health care community and the general public. Please feel free to browse this web site. Your access and use of the information contained herein is subject to the following terms and conditions and all applicable laws. By accessing and browsing this web site, you accept, without limitation or qualification, these terms and conditions and acknowledge that they supersede any other agreement between you and Ferring.

All information on this site is intended for US audiences only.

CERVIDIL, EUFLEXXA, FIRMAGON, NOCDURNA, ZOMACTON, and PREPOPIK are registered trademarks of Ferring B.V. CLENPIQ is a trademark of Ferring B.V.

©2008-2018 Ferring Pharmaceuticals.  GC/1722/2014/US(4)